COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE STUDIES LOCATION PRODUCT
Ability Pharmaceuticals ABTL0812 Biodrugs/ Drugs Cancer Lung, Endometrial and Pancreatic Cancer 4PhII España, EEUU, Francia e Israel ABTL0812
Therapeutic area: Cancer
Accure Therapeutics ACT-02 Biodrugs/ Drugs Central Nervous System Cognitive Impairment associated to neurodegenerative and psychiatric diseases (schizophrenia, Parkinson's disease) 2RP Spain ACT-02
Therapeutic area: Central Nervous System
Accure Therapeutics ACT-01 Biodrugs/ Drugs Central Nervous System
Ophthalmology and optometry
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis 3PhI ACT-01
Therapeutic area: Central Nervous System
Ophthalmology and optometry
Accure Therapeutics ACT-03 Biodrugs/ Drugs Central Nervous System Epilepsy 1NRP ACT-03
Therapeutic area: Central Nervous System
ALGENEX (Alternative Gene Expression S.L.) PCV2 vaccine Vaccines Infections Porcine Circovirus 2RP PCV2 vaccine
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) BDV vaccine Vaccines Infections Bovine Diarrhea Virus 1NRP BDV vaccine
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) Animal Influenza Vaccines Infections - 2RP Animal Influenza
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) RHDV vaccine Vaccines Infections Rabbit Hemorrhagic Disease Virus 6Reg. RHDV vaccine
Therapeutic area: Infections
ALGENEX (Alternative Gene Expression S.L.) COVID19 vaccine Vaccines Infections COVID19 vaccine with several proteins 1NRP COVID19 vaccine
Therapeutic area: Infections
Almirall Protein degraders Biodrugs/ Drugs Dermatology Dermatological conditions 1NRP Protein degraders
Therapeutic area: Dermatology
Almirall Bispecific Abs Biodrugs/ Drugs Dermatology Atopic dermatitis 1NRP Bispecific Abs
Therapeutic area: Dermatology
Almirall Bispecific anti_IL36 Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Inflammatory skin diseases 1NRP Bispecific anti_IL36
Therapeutic area: Autoimmune & Inflammation
Dermatology
Almirall Non-viral gene therapy Gene / Cell Therapy Dermatology Orphan dermatological conditions 1NRP Non-viral gene therapy
Therapeutic area: Dermatology
Almirall Sareciclina (ALM24001) Biodrugs/ Drugs Dermatology Acné 5PhIII China Sareciclina (ALM24001)
Therapeutic area: Dermatology
Almirall Wynzora Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Psoriasis 6Reg. EU Wynzora
Therapeutic area: Autoimmune & Inflammation
Dermatology
Almirall Tirbanibulin Biodrugs/ Drugs Dermatology Queratosis actínica 6Reg. EU Tirbanibulin
Therapeutic area: Dermatology
Almirall Translational Read-Through Inducers Biodrugs/ Drugs Dermatology Dystrophic Epidermolysis Bullosa 1NRP Translational Read-Through Inducers
Therapeutic area: Dermatology
Almirall Lebrikizumab (ALM17923) Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Atopic Dermatitis 5PhIII EU Lebrikizumab (ALM17923)
Therapeutic area: Autoimmune & Inflammation
Dermatology
Aptatargets APTOLL-02 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Multiple Sclerosis 2RP APTOLL-02
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Aptatargets APTOLL-01 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
Acute Ischemic Stroke 4PhII APTOLL-01
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Central Nervous System
APTUS Biotech AptaMnkQ2 Biodrugs/ Drugs Cancer Breast cancer treatment based on aptamers: ApMNKQ2 is a 29-nucleotide aptamer with high specificity and affinity to MNK1b that inhibits proliferation of breast cancer cells and, in animal experimental models, reduces the tumor size, cell proliferation and 1NRP AptaMnkQ2
Therapeutic area: Cancer
Araclon Biotech ABvac40 Biodrugs/ Drugs Central Nervous System Alzheimer's Disease 4PhII ABvac40
Therapeutic area: Central Nervous System
Archivel Farma RUTI Vaccines Cancer Bladder cancer. 3PhI RUTI
Therapeutic area: Cancer
Archivel Farma RUTI® Vaccines Infections Active tuberculosis - Latent Tuberculosis 4PhII Europe and South Africa RUTI®
Therapeutic area: Infections
Archivel Farma RUTI Vaccines Infections Clinical Trial to Evaluate the Efficacy of RUTI® Against SARS- COV-2 Infection in Healthcare Workers 2RP Spain RUTI
Therapeutic area: Infections
Archivel Farma RUTI Vaccines Infections Safety of RUTI® Vaccination in MDR-TB Patients 4PhII Ucrania RUTI
Therapeutic area: Infections
Arthex Biotech ARTHEx-01 Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
Myotonic dystrophy type 1 (DM1) 2RP Spain, UK, France, Germany ARTHEx-01
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
ATRYS HEALTH NILO1 Biodrugs/ Drugs Cancer
Central Nervous System
Brain tumor and brain lesions 1NRP Spain NILO1
Therapeutic area: Cancer
Central Nervous System
Bionos Biotech SL Pytren 4Q - Scorpio Therapeutics Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Pytren 4Q se presenta como una terapia sintomática para la enfermedad huérfana de Huntington mediante la reducción de los síntomas por activación y estimulación de la autofagia y de la actividad proteasómica. Es un compuesto antioxidante, activador de la 1NRP Pytren 4Q - Scorpio Therapeutics
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
CIBER Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing Gene / Cell Therapy Dermatology Epidermolysis Bullosa 1NRP Spain Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing
Therapeutic area: Dermatology
CIBER Pharmaceutical composition for use in the treatment of depression by the intranasal via Biodrugs/ Drugs Central Nervous System Treatment for depression 1NRP Pharmaceutical composition for use in the treatment of depression by the intranasal via
Therapeutic area: Central Nervous System
CIBER Gene editing medicinal product for Epidermolysis Bullosa Gene / Cell Therapy Dermatology Epidermolysis Bullosa. Autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by Crispr/Cas9-mediated 2RP Spain Gene editing medicinal product for Epidermolysis Bullosa
Therapeutic area: Dermatology
CIBER TARGETED INTERVENTIONS DIRECTED AT REDUCING THE LEVELS OF CIRCULATING SUCCINATE IN A SUBJECT Biodrugs/ Drugs Cardiovascular and circulatory systems The present invention comprises a kit to measure the ratio of succinate-producing bacteria to succinate-consuming bacteria, a diet intervention and a pharmacological or probiotic product directed at modifying the ratio of succinate-producing bacteria to s 1NRP Spain TARGETED INTERVENTIONS DIRECTED AT REDUCING THE LEVELS OF CIRCULATING SUCCINATE IN A SUBJECT
Therapeutic area: Cardiovascular and circulatory systems
CIBER In Vivo Lentiviral Gene Theraphy for the treatment of Primary Hyperoxaluria type 1 Gene / Cell Therapy Genetic Diseases and Dysmorphic syndromes
Kidney and Genitourinary system
Primary Hyperoxaluria type 1 2RP Spain In Vivo Lentiviral Gene Theraphy for the treatment of Primary Hyperoxaluria type 1
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Kidney and Genitourinary system
CIBER GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER Biodrugs/ Drugs Others The present invention is a gut microbiota composition comprising a wide range of species of genus with a vast array of applications for use in the specific prevention and/or treatment of a mental disorder with memory impairment in a subject. 1NRP Spain GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER
Therapeutic area: Others
CIBER GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE Gene / Cell Therapy Autoimmune & Inflammation GRAFT versus HOST DISEASE 2RP Spain GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE
Therapeutic area: Autoimmune & Inflammation
CIBER MicroRNA for the treatment of obesity Gene / Cell Therapy Metabolic / Endocrinology Obesity treatment 1NRP MicroRNA for the treatment of obesity
Therapeutic area: Metabolic / Endocrinology
CIBER Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease Biodrugs/ Drugs Central Nervous System Charcot-Marie-Tooth disease. Two compounds in particular, a mitochondrial antioxidant (MitoQ) and an antibiotic (florfenicol). 1NRP Spain Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease
Therapeutic area: Central Nervous System
CIBER COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS Biodrugs/ Drugs Metabolic / Endocrinology obesity-related metabolic disorders, obesity-related tissue dysfunction 1NRP COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
Therapeutic area: Metabolic / Endocrinology
CIBER Therapeutic use of acid ceramidase in the treatment of Niemann-Pick type C disease Biodrugs/ Drugs Central Nervous System
Digestive System
Metabolic / Endocrinology
Respiratory and Pulmonary system
The objective is to administer recombinant acid ceramidase (ACDase) as a new treatment in type C Niemann-Pick disease. ACDase, whose expression is depressed in NPC disease, is capable of suppressing the induction of STARD1. 1NRP Spain Therapeutic use of acid ceramidase in the treatment of Niemann-Pick type C disease
Therapeutic area: Central Nervous System
Digestive System
Metabolic / Endocrinology
Respiratory and Pulmonary system
CIBER Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use Biodrugs/ Drugs Autoimmune & Inflammation anti-inflammatory diseases 1NRP Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use
Therapeutic area: Autoimmune & Inflammation
CIBER Gene Therapy for the treatment of Diamond-Blackfan Anemia Gene / Cell Therapy Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
Diamond-Blackfan Anemia 2RP Europe Gene Therapy for the treatment of Diamond-Blackfan Anemia
Therapeutic area: Blood and Lymphatic systems
Genetic Diseases and Dysmorphic syndromes
DIOMUNE SL IV1303 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV 2RP IV1303
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
ENTRECHEM EC-8042 iv for Ewing sarcoma Biodrugs/ Drugs Cancer Solid tumours 2RP EC-8042 iv for Ewing sarcoma
Therapeutic area: Cancer
ENTRECHEM EC-8042 iv for Triple negative breast cancer Biodrugs/ Drugs Cancer Triple negative breast cancer 2RP EC-8042 iv for Triple negative breast cancer
Therapeutic area: Cancer
ENTRECHEM EC-70124 po for TNBC Biodrugs/ Drugs Cancer Triple negative breast cancer 2RP EC-70124 po for TNBC
Therapeutic area: Cancer
ENTRECHEM EC-70124 po for prostate cancer Biodrugs/ Drugs Cancer Castration resistant prostate cancer 2RP EC-70124 po for prostate cancer
Therapeutic area: Cancer
ENTRECHEM EC-8042 iv for liposarcoma Biodrugs/ Drugs Cancer liposarcoma myxoide 2RP EC-8042 iv for liposarcoma
Therapeutic area: Cancer
ENTRECHEM EC-70124 po for AML Biodrugs/ Drugs Cancer Acute myeloid leukemia 2RP EC-70124 po for AML
Therapeutic area: Cancer
ENTRECHEM Brasilicardin analogs Biodrugs/ Drugs Autoimmune & Inflammation Immunosupression 1NRP Brasilicardin analogs
Therapeutic area: Autoimmune & Inflammation
FERRER FNP-117 Gene / Cell Therapy Central Nervous System Spinal Cord Injury 4PhII FNP-117
Therapeutic area: Central Nervous System
FERRER FNP-150 Biodrugs/ Drugs Central Nervous System Parkinson 4PhII FNP-150
Therapeutic area: Central Nervous System
FERRER FNP-122 Biodrugs/ Drugs Central Nervous System Neuromotor disorders 5PhIII FNP-122
Therapeutic area: Central Nervous System
FERRER FNP-202 Biodrugs/ Drugs Respiratory and Pulmonary system Pulmonary Arterial Hypertension 5PhIII FNP-202
Therapeutic area: Respiratory and Pulmonary system
FERRER FNP-911 Biodrugs/ Drugs Analgesia & Pain Osteoarthritis 1NRP FNP-911
Therapeutic area: Analgesia & Pain
FERRER FNP-010 Biodrugs/ Drugs Central Nervous System Cyclic Vomiting Syndrome 4PhII FNP-010
Therapeutic area: Central Nervous System
FERRER FNP-080 Biodrugs/ Drugs Cardiovascular and circulatory systems Secondary prevention of cardiovascular accidents 3PhI FNP-080
Therapeutic area: Cardiovascular and circulatory systems
FERRER FNP-120 Biodrugs/ Drugs Ophthalmology and optometry Diabetic Retinopathy 4PhII FNP-120
Therapeutic area: Ophthalmology and optometry
FUND. PROGRESO Y SALUD FISEVI-19003. Furan, Thiophene or y-Lactam serterterpene tetronic acids useful as antiviral compounds against infections caused by Human Adenovirus Biodrugs/ Drugs Infections Multirresistant infections 2RP FISEVI-19003. Furan, Thiophene or y-Lactam serterterpene tetronic acids useful as antiviral compounds against infections caused by Human Adenovirus
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FISEVI-19016. Novel Salicylamide derivatives for the treatment of viral infections Biodrugs/ Drugs Infections Multirresistant infections 2RP FISEVI-19016. Novel Salicylamide derivatives for the treatment of viral infections
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FIMABIS-15008 RECOMBINANT PROTEIN AS ANTIVIRAL Biodrugs/ Drugs Infections Viral infection 1NRP FIMABIS-15008 RECOMBINANT PROTEIN AS ANTIVIRAL
Therapeutic area: Infections
FUND. PROGRESO Y SALUD CABIMER- 21001 Use of melatonin to improve the therapeutic potential of mesenchymal stem cells in cancer Biodrugs/ Drugs Cancer Cancer 1NRP CABIMER- 21001 Use of melatonin to improve the therapeutic potential of mesenchymal stem cells in cancer
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FIBICO-14003 LISED OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MUSCULAR SKELETAL INJURIES Gene / Cell Therapy Musculoskeletal Disorders Musculoskeletal disorders 1NRP FIBICO-14003 LISED OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF MUSCULAR SKELETAL INJURIES
Therapeutic area: Musculoskeletal Disorders
FUND. PROGRESO Y SALUD FISEVI-16001. Compositions for the treatment of ischemic ulcers and stretch marks Biodrugs/ Drugs Dermatology Treatment of ischemic ulcers and stretch marks 2RP FISEVI-16001. Compositions for the treatment of ischemic ulcers and stretch marks
Therapeutic area: Dermatology
FUND. PROGRESO Y SALUD CABIMER-18004 LSD1 INHIBITORS FOR USE IN THE TREATMENT OF TYPE 2 DIABETES Biodrugs/ Drugs Metabolic / Endocrinology Type 2 Diabetes 1NRP CABIMER-18004 LSD1 INHIBITORS FOR USE IN THE TREATMENT OF TYPE 2 DIABETES
Therapeutic area: Metabolic / Endocrinology
FUND. PROGRESO Y SALUD FISEVI-13002 CANNABIOTICS Biodrugs/ Drugs Cancer Multiple myeloma 2RP FISEVI-13002 CANNABIOTICS
Therapeutic area: Cancer
FUND. PROGRESO Y SALUD FISEVI-15019. Piperazine derivatives as antiviral agents with increased therapeutic activity Biodrugs/ Drugs Infections Multirresistant infections 2RP FISEVI-15019. Piperazine derivatives as antiviral agents with increased therapeutic activity
Therapeutic area: Infections
FUND. PROGRESO Y SALUD FISEVI-18006. Hemorrhagic cerebrospinal fluid neural stem cells Biodrugs/ Drugs Central Nervous System Treatment of infants for different neurogical disorders 2RP FISEVI-18006. Hemorrhagic cerebrospinal fluid neural stem cells
Therapeutic area: Central Nervous System
FUND. PROGRESO Y SALUD CABIMER-19002 NON-VIRAL VECTORS FROM MESOPOROUS NANOPARTICLES FOR THEIR APPLICATION IN GENE THERAPY FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA Gene / Cell Therapy Ophthalmology and optometry Degenerative diseases of the retina 1NRP CABIMER-19002 NON-VIRAL VECTORS FROM MESOPOROUS NANOPARTICLES FOR THEIR APPLICATION IN GENE THERAPY FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA
Therapeutic area: Ophthalmology and optometry
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) New generation of peptides Biodrugs/ Drugs Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
Chronic complications of Diabetes / Choric kidney disease 2RP New generation of peptides
Therapeutic area: Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Advanced cell therapies Gene / Cell Therapy Ophthalmology and optometry Eye rare diseases 4PhII Spain / Europe Advanced cell therapies
Therapeutic area: Ophthalmology and optometry
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Peptide derived from a natural compound Biodrugs/ Drugs Autoimmune & Inflammation
Metabolic / Endocrinology
Osteoporosis treatment 1NRP Peptide derived from a natural compound
Therapeutic area: Autoimmune & Inflammation
Metabolic / Endocrinology
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Advanced cell therapies Gene / Cell Therapy Blood and Lymphatic systems
Cancer
Oncology / Haematological disorders 3PhI Spain / US Advanced cell therapies
Therapeutic area: Blood and Lymphatic systems
Cancer
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) Mutli-target siRNA approach Gene / Cell Therapy Autoimmune & Inflammation
Kidney and Genitourinary system
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI) 2RP Mutli-target siRNA approach
Therapeutic area: Autoimmune & Inflammation
Kidney and Genitourinary system
Fundacion MEDINA MDN-088 Biodrugs/ Drugs Cancer Breast, Colon & Lung Cancer 1NRP MDN-088
Therapeutic area: Cancer
Fundacion MEDINA MDN-0145; MDN-0146 Biodrugs/ Drugs Central Nervous System Parkinson 1NRP MDN-0145; MDN-0146
Therapeutic area: Central Nervous System
Fundacion MEDINA MDN-0109, MDN-110, MDN-111, MDN- 112 Biodrugs/ Drugs Infections Malaria 1NRP MDN-0109, MDN-110, MDN-111, MDN- 112
Therapeutic area: Infections
Fundacion MEDINA MDN-0090 Biodrugs/ Drugs Cancer Pancreatic Cancer 1NRP MDN-0090
Therapeutic area: Cancer
Fundacion MEDINA MDN-005 Biodrugs/ Drugs Central Nervous System
Musculoskeletal Disorders
Amyotrophic lateral sclerosis (ALS) 1NRP MDN-005
Therapeutic area: Central Nervous System
Musculoskeletal Disorders
Highlight Therapeutics BO-112 Biodrugs/ Drugs Cancer Solid tumors in patients with liver metastasis from colorectal cancer or gastric/gastro-esophageal junction cancer. Patients with advanced and/or metastatic melanoma. 4PhII BO-112
Therapeutic area: Cancer
Histocell HC016 Biodrugs/ Drugs Central Nervous System Acute Spinal Cord Injury 4PhII HC016
Therapeutic area: Central Nervous System
Histocell HR004 Biodrugs/ Drugs Musculoskeletal Disorders Bone Regeneration 4PhII HR004
Therapeutic area: Musculoskeletal Disorders
Histocell HR016 Biodrugs/ Drugs Respiratory and Pulmonary system Acute Lung Injury 3PhI HR016
Therapeutic area: Respiratory and Pulmonary system
Institut Quimic de Sarrià (IQS) Chondro-implant Gene / Cell Therapy Cardiovascular and circulatory systems Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure 1NRP Chondro-implant
Therapeutic area: Cardiovascular and circulatory systems
Institut Quimic de Sarrià (IQS) Cardio-implant Gene / Cell Therapy Cardiovascular and circulatory systems PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct 1NRP Cardio-implant
Therapeutic area: Cardiovascular and circulatory systems
IRYCIS New compound for the treatment of isquemical stroke Biodrugs/ Drugs Central Nervous System Isquemic stroke 1NRP Spain New compound for the treatment of isquemical stroke
Therapeutic area: Central Nervous System
Laminar Pharma LP226A1 Biodrugs/ Drugs Central Nervous System Alzheimer's Disease 2RP LP226A1
Therapeutic area: Central Nervous System
Laminar Pharma LP30171 Biodrugs/ Drugs Cancer
Metabolic / Endocrinology
Metabolic Diseases, cancer 1NRP LP30171
Therapeutic area: Cancer
Metabolic / Endocrinology
Laminar Pharma LP561A1 Biodrugs/ Drugs Cancer Glioma and other solid tumours 4PhII LP561A1
Therapeutic area: Cancer
Laminar Pharma LP205A1 Biodrugs/ Drugs Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
Cardiovascular and Metabolic Diseases, CNS, 1NRP LP205A1
Therapeutic area: Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
Laminar Pharma LPA181 Biodrugs/ Drugs Central Nervous System Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company 2RP LPA181
Therapeutic area: Central Nervous System
Laminar Pharma LP204A1 Biodrugs/ Drugs Autoimmune & Inflammation
Cardiovascular and circulatory systems
Inflammation, Cardiovascular 1NRP LP204A1
Therapeutic area: Autoimmune & Inflammation
Cardiovascular and circulatory systems
Leitat COVID Biodrugs/ Drugs Infections Neutralizing antibodies 1NRP COVID
Therapeutic area: Infections
Leitat Anti-S100A4 Biodrugs/ Drugs Cancer
Metabolic / Endocrinology
Anti-cancer Anti-metastasis Anti-fibrosis 1NRP Anti-S100A4
Therapeutic area: Cancer
Metabolic / Endocrinology
Leukos Biotech LK-01 Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
AML 3PhI LK-01
Therapeutic area: Blood and Lymphatic systems
Cancer
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System Friedreich's Ataxia 4PhII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System
Kidney and Genitourinary system
Acute X-linked Adrenoleukodystrophy (cALD; cerebral ALD) 4PhII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Kidney and Genitourinary system
Minoryx MIN-102 (leriglitazone) Biodrugs/ Drugs Central Nervous System
Metabolic / Endocrinology
Chronic X-linked Adrenoleukodystrophy (AMN; Adrenomyeloneuropathy) 5PhIII MIN-102 (leriglitazone)
Therapeutic area: Central Nervous System
Metabolic / Endocrinology
NATAC Retriacyl Biodrugs/ Drugs Ophthalmology and optometry Retinitis Pigmentosa 5PhIII Europe Retriacyl
Therapeutic area: Ophthalmology and optometry
Neurofix NFX91 Biodrugs/ Drugs Others Sleep disorders 1NRP NFX91
Therapeutic area: Others
Neurofix NFX88 Biodrugs/ Drugs Analgesia & Pain
Central Nervous System
Neuropathic pain 4PhII Spain NFX88
Therapeutic area: Analgesia & Pain
Central Nervous System
Neurofix NFX81 Biodrugs/ Drugs Central Nervous System Spinal Cord Injuries 2RP Spain NFX81
Therapeutic area: Central Nervous System
ONA Therapeutics ONA-1 Biodrugs/ Drugs Cancer Advanced cancer 1NRP ONA-1
Therapeutic area: Cancer
Oryzon Iadademstat (ORY-2001) selective LSD1 inhibitor Biodrugs/ Drugs Cancer AML (Elderly Unfit) - Alice Study (Combo with Azacitidine) 4PhII Iadademstat (ORY-2001) selective LSD1 inhibitor
Therapeutic area: Cancer
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression is ASD - Reimagine Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression in AD - Reimagine-AD Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Alzheimer's Disease (Mild-Moderate) - Etheral Study monotherapy 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression in ADHD - Reimagine Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Multiple Sclerosis (RR & SP) - Sateen Study monotherapy 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon HDAC-6/Other undisclosed Biodrugs/ Drugs Undisclosed 2RP HDAC-6/Other undisclosed
Therapeutic area:
Oryzon ORY-3001 - selective LSD1 inhibitor Biodrugs/ Drugs Others Non-Oncological 2RP ORY-3001 - selective LSD1 inhibitor
Therapeutic area: Others
Oryzon Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor Biodrugs/ Drugs Central Nervous System Aggression in BPD - Reimagine Study 4PhII Vafidemstat (ORY-2001) - CNS optimized LSD1 inhibitor
Therapeutic area: Central Nervous System
Oryzon Iadademstat (ORY-2001) selective LSD1 inhibitor Biodrugs/ Drugs Cancer SCLC (First Line Relapsed) - Clepsidra Study (Combo with Platinum/Etoposide) 4PhII Iadademstat (ORY-2001) selective LSD1 inhibitor
Therapeutic area: Cancer
PaloBiofarma PBF-1129 Biodrugs/ Drugs Cancer Lung Cancer 3PhI Spain PBF-1129
Therapeutic area: Cancer
PaloBiofarma PBF-677 Biodrugs/ Drugs Digestive System Colitis 4PhII Spain PBF-677
Therapeutic area: Digestive System
PaloBiofarma PBF-999 Biodrugs/ Drugs Cancer Solid Tumors 3PhI Spain PBF-999
Therapeutic area: Cancer
PaloBiofarma PBF-509 Biodrugs/ Drugs Cancer
Central Nervous System
Lung Cancer 4PhII Spain PBF-509
Therapeutic area: Cancer
Central Nervous System
PaloBiofarma PBF680 Biodrugs/ Drugs Respiratory and Pulmonary system Asthma 4PhII Spain PBF680
Therapeutic area: Respiratory and Pulmonary system
Peptomyc OMO-103 Biodrugs/ Drugs Cancer First pan-MYC inhibitor in the clinic 3PhI Spain OMO-103
Therapeutic area: Cancer
PharmaMar TRABECTEDIN + Radiotherapy Biodrugs/ Drugs Cancer Soft Tissue Sarcoma 2nd/3rd line. 6Reg. TRABECTEDIN + Radiotherapy
Therapeutic area: Cancer
PharmaMar PM14 Biodrugs/ Drugs Cancer Sonf Tissue Sarcoma 3PhI PM14
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183)+IRINOTECAN Biodrugs/ Drugs Cancer Small Cell Lung Cancer 2nd line 4PhII EUROPE LURBINECTEDIN (PM1183)+IRINOTECAN
Therapeutic area: Cancer
PharmaMar LURBINECTEDIN (PM1183) Biodrugs/ Drugs Cancer Mesothelioma 2nd line 4PhII LURBINECTEDIN (PM1183)
Therapeutic area: Cancer
PharmaMar PM14 Biodrugs/ Drugs Cancer Solid tumors 3PhI EU PM14
Therapeutic area: Cancer
REIG JOFRE P0223 Biodrugs/ Drugs Dermatology Skin infection 6Reg. Spain P0223
Therapeutic area: Dermatology
REIG JOFRE P0265 Biodrugs/ Drugs Dermatology Skin infections 5PhIII Spain, Mexico P0265
Therapeutic area: Dermatology
Sanifit SNF472 Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Calciphylaxis 5PhIII SNF472
Therapeutic area: Cardiovascular and circulatory systems
Metabolic / Endocrinology
Sanifit SNF472 Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Peripheral Arterial Disease (dialysis) 5PhIII SNF472
Therapeutic area: Cardiovascular and circulatory systems
Metabolic / Endocrinology
SOM Biotech SOM3355 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Chorea in Huntington's disease 4PhII Phase IIb: EU SOM3355
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
SOM Biotech SOM0208 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Niemann-Pick treatment 2RP SOM0208
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
SOM Biotech SOM1311 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
Phenylketonuria 4PhII SOM1311
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
SOM Biotech SOM0061 Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
COVID-19 4PhII SOM0061
Therapeutic area: Infections
Respiratory and Pulmonary system
SOM Biotech SOM0044 Biodrugs/ Drugs Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Parkinson’s disease 2RP SOM0044
Therapeutic area: Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Sylentis siRNA / SYL1801 Biodrugs/ Drugs Ophthalmology and optometry Retina 3PhI siRNA / SYL1801
Therapeutic area: Ophthalmology and optometry
Sylentis Tivanisirán / SYL1001 Biodrugs/ Drugs Ophthalmology and optometry Dry Eye Syndrome 5PhIII Tivanisirán / SYL1001
Therapeutic area: Ophthalmology and optometry
Sylentis Bamosiran / SYL040012 Biodrugs/ Drugs Ophthalmology and optometry Ocular Hypertension, Glaucoma 4PhII Bamosiran / SYL040012
Therapeutic area: Ophthalmology and optometry
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Head & Neck Cancer 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Retinoblastoma 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-11 Gene / Cell Therapy Cancer Solid Tumors 2RP VCN-11
Therapeutic area: Cancer
VCN Biosciences VCN-01 Gene / Cell Therapy Cancer Pancreatic cancer 3PhI Spain VCN-01
Therapeutic area: Cancer
VCN Biosciences VCN-02 Gene / Cell Therapy Cancer Solid Tumors 1NRP VCN-02
Therapeutic area: Cancer
VENTER PHARMA LacTEST 2,7 g Biodrugs/ Drugs Digestive System Evaluation of hypolactasia 5PhIII LacTEST 2,7 g
Therapeutic area: Digestive System
Vivia Biotech Vivia 009 Biodrugs/ Drugs Blood and Lymphatic systems
Central Nervous System
Non Hodgkin Lymphoma, CNS 2RP Europe Vivia 009
Therapeutic area: Blood and Lymphatic systems
Central Nervous System
Vivia Biotech Vivia 011 Biodrugs/ Drugs Metabolic / Endocrinology Obesity, Diabetes 1NRP Vivia 011
Therapeutic area: Metabolic / Endocrinology
ZENDAL MTBVAC Vaccines Infections
Respiratory and Pulmonary system
MTBVAC is a live freeze dried vaccine based on a genetically attenuated strain of a clinical isolate of M. tuberculosis manufactured by BIOFABRI. MTBVAC is now in Phase 2a in newborns infants and a Phase2a in BCG-vaccinated adults in South Africa 4PhII MTBVAC
Therapeutic area: Infections
Respiratory and Pulmonary system